Synairgen (AIM:SNG) appoints a permanent chief medical officer as they intensify drug development.

Synairgen PLC (AIM:SNG, OTC:SYGGF) has welcomed Dr. Marcin Mankowski, a veteran pharmaceutical physician and drug developer, as its chief medical officer with immediate effect.

The company, currently advancing its SNG001 project – an inhaled formulation containing the immunomodulatory antiviral protein, interferon beta – established this dedicated role to align with their advancing clinical development.

Since 2018, Dr. Mankowski had been associated with Synairgen, serving as its interim CMO and a clinical trials consultant. Before his tenure at Synairgen, he co-established and led tranScrip, a prominent contract drug development firm, bringing over 27 years of industry expertise.

Expressing enthusiasm about his new role, Dr. Mankowski remarked, “I’m eager to deepen my collaboration with the Synairgen team, directing our efforts towards more refined clinical trials of SNG001 and optimizing its therapeutic potential.”

Synairgen’s CEO, Richard Marsden, commented on the appointment: “Having Marcin onboard full-time as CMO is a pleasure. His continuous guidance on our clinical trials since 2018 not only emphasizes his faith in our drug but also his profound understanding of both the Company and SNG001.

His extensive experience in spearheading global clinical development initiatives will be crucial as we delve into more advanced clinical trials of SNG001

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.